CONGRESS NEWS

Highlights from the 18^th biannual symposium Acute Leukaemias (ISALXVIII)

SUMMARY

Leading topics at the international symposium Acute Leukaemias (ISALXVIII) in 2023 were: the new classifications for acute leukaemia, interpretation of clonal haematopoiesis (CHIP), advancing insights of venetoclax-azacitidine (VEN-AZA) administration and associated supportive care, the position of new treatment options in fit and unfit patients, the renewed role of maintenance, and first steps in bringing immunotherapy to the acute myeloid leukaemia (AML) population.

(BELG J HEMATOL 2023;14(4):186–91)

BSTH 2022 Abstracts

Presidential symposium EBMT 2022

SUMMARY

During the presidential symposium of the 48^th Annual Meeting of the EBMT (2022), the Van Bekkum Award and seven top clinical abstracts were discussed. These presentations will be covered in this report.

(BELG J HEMATOL 2022;13(4):169–73)

Highlights from EAHAD 2022

SUMMARY

From 1–4 February 2022, more than 2,300 delegates joined and interacted online during the 2022 European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress. During these days, EAHAD 2022 was once again the virtual ‘place-to-be’ for the latest in the field of haemophilia and allied disorders.

(BELG J HEMATOL 2022;13(3):133–6)

18th International Myeloma Workshop 2021

SUMMARY

The diagnostic and therapeutic landscape of multiple myeloma (MM) has been in constant evolution, resulting in many novel treatment opportunities for patients with MM, though many challenges remain in providing optimal care for patients with MM. In this article, several recent updates with regard to the diagnosis and treatment of MM, as presented at the 18^th International Myeloma Workshop (IMW), have been summarised. In this summary, two main topics have been highlighted: 1) early treatment of high-risk smouldering MM, in combination with the development of non-invasive methods for risk stratification of smouldering MM, using circulating tumour cells and 2) updates on trials regarding novel treatment modalities, including novel combination regimens in newly diagnosed and relapsed MM patients, as well as novel immune therapies, with a focus on CAR-T cell therapy and bispecific antibodies.

(BELG J HEMATOL 2022;13(2):95–9)

Highlights of the 16^th International Conference on Malignant Lymphoma

SUMMARY

This report summarises some useful studies presented during the 2021 International Conference on Malignant Lymphoma (ICML, virtual, June 18–22).

(BELG J HEMATOL 2021;12(8):355–60)

Highlights in chronic lymphocytic leukaemia

(BELG J HEMATOL 2021;12(5):183-8)